A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.
A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.
In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Ahead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.
A new study is suggesting that by targeting a specific microRNA molecule (miR-141) it may be possible to stop the cascade of events that lead to metastasis in men with prostate cancer.
A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.
A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.
Medical researchers at Indiana University Bloomington are reporting that prostate cancer may be much more closely related to Ewing’s sarcoma than previously recognized.
ESMO 2016: Early Results for Pembrolizumab Against Metastatic Enzalutamide-Refractory Prostate Cancer
Pembrolizumab showed clinical activity against some cases of enzalutamide-refractory metastatic castration-resistant prostate cancer.
Investigators think they may have found a strong predictor of which men with prostate cancer will develop resistance to androgen deprivation therapy.